Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07136103 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants | PHASE1 | ACTIVE NOT_RECRUITING | 32 | — | — | Aug 19, 2025 | Jun 1, 2026 | Apr 29, 2026 | 1 | United States |
Cmax of ABBV-277
Tmax of ABBV-277
Terminal phase elimination rate constant (beta) of ABBV-277
Terminal phase elimination half-life of ABBV-277
AUCt of ABBV-277
AUCinf of ABBV-277
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-277-Dose A | EXPERIMENTAL | Participants will receive ABBV-277 Dose A on day 1 and followed for 196 days |
| Group 1: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 2: ABBV-277-Dose B | EXPERIMENTAL | Participants will receive ABBV-277 Dose B on day 1 and followed for 196 days |
| Group 2: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 3: ABBV-277-Dose C | EXPERIMENTAL | Participants will receive ABBV-277 Dose C on day 1 and followed for 196 days |
| Group 3: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 4: ABBV-277-Dose D | EXPERIMENTAL | Participants will receive ABBV-277 Dose D on day 1 and followed for 196 days |
| Group 4: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 5: ABBV-277-Dose E | EXPERIMENTAL | Participants will receive ABBV-277 Dose E on day 1 and day 2 and followed for 196 days |
| Group 5: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and day 2 and followed for 196 days |
| Name | Type | Description |
|---|---|---|
| ABBV-277 | DRUG | • Intravenous (IV) infusion |
| Placebo | DRUG | • Intravenous (IV) infusion |
Inclusion Criteria: * Body weight ≥ 35 kg * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile neurological examination, and ...